Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

HDAC inhibitors sodium butyrate and sodium valproate do not affect human NCOR1 and NCOR2 gene expression in HL-60 cells

Jiri Vrba, Katerina Trtkova, Jitka Ulrichova

. 2011 ; 155 (3) : 259-262.

Language English Country Czech Republic

Persistent link   https://www.medvik.cz/link/bmc12000428

Aim. This study was designed to examine whether the class I and class IIa histone deacetylase (HDAC) inhibitors, sodium butyrate and sodium valproate alter the expression of human NCOR1 and/or NCOR2 genes coding for N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors), respectively. Methods. Human leukemia HL-60 cells were treated for 24 h with 0.5 and 1 mM sodium butyrate, 1 to 3 mM sodium valproate, 1 mcM all-trans retinoic acid (ATRA) or cotreated with 1 mcM ATRA and 0.5 mM sodium butyrate. The acetylation of histones H3 and H4 was analysed by western blotting. The levels of NCOR1 and NCOR2 mRNA were determined by quantitative real-time PCR. Expression of NCF2 gene coding for the NADPH oxidase subunit p67phox was evaluated as a marker of myeloid differentiation. Results. Both butyrate and valproate increased the acetylation of histone H3 at Lys9 and/or Lys14 as well as histone H4 at Lys12. Both HDAC inhibitors caused a significant increase in NCF2 mRNA levels without affecting NCOR1 or NCOR2 mRNA levels. Similarly, ATRA alone or in combination with butyrate induced NCF2 gene expression without any significant influence on the expression of NCOR1 or NCOR2 genes. Conclusion. We conclude that inhibitors of class I and class IIa HDACs do not alter the expression of human NCOR1 or NCOR2 genes and that the onset of myeloid differentiation is not accompanied by induction or repression of these genes in HL-60 cells.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc12000428
003      
CZ-PrNML
005      
20120215154148.0
007      
ta
008      
120113s2011 xr fd f 000 0eng||
009      
AR
024    7_
$a 10.5507/bp.2011.033 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Vrba, Jiří, $d 1971- $7 xx0042118 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc
245    10
$a HDAC inhibitors sodium butyrate and sodium valproate do not affect human NCOR1 and NCOR2 gene expression in HL-60 cells / $c Jiri Vrba, Katerina Trtkova, Jitka Ulrichova
504    __
$a Literatura $b 20
520    9_
$a Aim. This study was designed to examine whether the class I and class IIa histone deacetylase (HDAC) inhibitors, sodium butyrate and sodium valproate alter the expression of human NCOR1 and/or NCOR2 genes coding for N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors), respectively. Methods. Human leukemia HL-60 cells were treated for 24 h with 0.5 and 1 mM sodium butyrate, 1 to 3 mM sodium valproate, 1 mcM all-trans retinoic acid (ATRA) or cotreated with 1 mcM ATRA and 0.5 mM sodium butyrate. The acetylation of histones H3 and H4 was analysed by western blotting. The levels of NCOR1 and NCOR2 mRNA were determined by quantitative real-time PCR. Expression of NCF2 gene coding for the NADPH oxidase subunit p67phox was evaluated as a marker of myeloid differentiation. Results. Both butyrate and valproate increased the acetylation of histone H3 at Lys9 and/or Lys14 as well as histone H4 at Lys12. Both HDAC inhibitors caused a significant increase in NCF2 mRNA levels without affecting NCOR1 or NCOR2 mRNA levels. Similarly, ATRA alone or in combination with butyrate induced NCF2 gene expression without any significant influence on the expression of NCOR1 or NCOR2 genes. Conclusion. We conclude that inhibitors of class I and class IIa HDACs do not alter the expression of human NCOR1 or NCOR2 genes and that the onset of myeloid differentiation is not accompanied by induction or repression of these genes in HL-60 cells.
650    _2
$a HL-60 buňky $x imunologie $x metabolismus $7 D018922
650    _2
$a korepresorové proteiny $x genetika $x imunologie $x metabolismus $7 D056970
650    _2
$a histondeacetylasa 1 $x farmakokinetika $7 D056284
650    _2
$a histondeacetylasa 2 $x farmakokinetika $7 D056464
650    _2
$a receptory cytoplazmatické a nukleární $x farmakokinetika $7 D018160
650    _2
$a butyráty $x antagonisté a inhibitory $x metabolismus $7 D002087
650    _2
$a kyselina valproová $x analogy a deriváty $x antagonisté a inhibitory $x metabolismus $7 D014635
650    _2
$a aktivace transkripce $x genetika $x účinky léků $7 D015533
650    _2
$a financování organizované $7 D005381
650    _2
$a genetické techniky $x využití $7 D005821
700    1_
$a Smešný Trtková, Kateřina, $7 xx0143535 $u Laboratory of Molecular Pathology, Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc $d 1965-
700    1_
$a Ulrichová, Jitka, $d 1956- $7 ola2002158251 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc
773    0_
$t Biomedical papers $x 1213-8118 $g Roč. 155, č. 3 (2011), s. 259-262 $w MED00012606
910    __
$a ABA008 $b A 1502 $c 958 $y 2
990    __
$a 20120112154833 $b ABA008
991    __
$a 20120215154129 $b ABA008
999    __
$a ok $b bmc $g 893114 $s 757109
BAS    __
$a 3
BMC    __
$a 2011 $b 155 $c 3 $d 259-262 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$a 2012-03/dkmv

Find record

Citation metrics

Archiving options